• May 11, 2021
    • Loading stock data...
  • Innocan Pharma’s Cosmetic Clinical Study Indicates a 90% Wrinkle Reduction After Using Its SHIR(TM) Premium CBD Facial Serum

    LinkedIn

    Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – October 15, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce today that it has completed a cosmetic clinical study on 20 volunteers that presented a 90 – 95facial skin wrinkle reduction after using its SHIR ™ Premium CBD Facial Serum.

    “Achieving these amazing results is due to the combination of active ingredients with a specific amount of CBD, result in a tremendous facial skin improvement. The SHIR Beauty & Science skincare brand combines the benefits of CBD’s most effective ingredients into an innovative formula which is leading to visible fast-acting results. Each ingredient was carefully chosen to provide a synergistic effect, working in harmony with each other. The high satisfaction of the volunteers enrolled at the study may indicate a high potential of the targeted market to welcome SHIR Beauty & Science skincare line of products and accelerate InnoCan market penetration,” stated Iris Bincovich, Chief Executive Officer of Innocan.”

    The clinical study was conducted by UPTEC, Science and Technology Park of the University of Porto, Portugal which is an independent lab. The findings of the clinical study were consistent with the main principles of ICH GCP, Helsinki declaration and Portuguese legal requirements.

    About Innocan

    Innocan Israel, a wholly owned subsidiary of the Company, is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

    Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz Head of the Laboratory of Membrane and Liposome Research of The Hebrew University of Jerusalem, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

    For further information, please contact:

    Innocan Pharma Corporation
    Iris Bincovich, CEO
    +972-54-3012842
    info@innocanpharma.com

    For graphics and begore-after photos click here: https://finance.yahoo.com/news/innocan-pharmas-cosmetic-clinical-study-200000356.html

    Share.

    About Author

    Comments are closed.